Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In a new cross-trial analysis of patients with heart failure with reduced ejection fraction, researchers predict that a comprehensive strategy combining several pharmacological approaches reduces hospitalization and mortality compared with conventional therapy.
A new biomimetic drug delivery system consisting of nanoparticles that are coated with macrophage membrane and responsive to reactive oxygen species enables targeted pharmacotherapy for atherosclerosis in mice while also suppressing local inflammation by sequestering inflammatory factors.
Similar rates of infection and device-related deaths were observed between patients who received a recycled cardiac device and patients who received a new device.
According to five new studies, therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) is not associated with an increased risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or with an increased risk of severe disease or in-hospital death among patients with COVID-19.
Individuals with obesity have an increased prevalence of the Bacteroides 2 enterotype, which is associated with systemic inflammation and disease. However, statin therapy is associated with a reduced prevalence of this dysbiosis in individuals with obesity.
Using cardiac MRI-derived structural and functional data from UK Biobank participants, Aragam and colleagues identified novel variants at 45 genetic loci that associate with risk of dilated cardiomyopathy.
According to findings from the POPular AGE trial, clopidogrel treatment is associated with a lower bleeding risk compared with ticagrelor in older patients with non-ST-elevation acute coronary syndrome.
A new study shows that regulatory T cells have essential roles in atherosclerotic plaque regression by promoting the resolution of plaque inflammation through suppression of macrophage and T cell pro-inflammatory responses and induction of a pro-resolving macrophage phenotype.
An adverse childhood family environment is associated with an increased rate of cardiovascular disease and death in middle age, according to a longitudinal cohort study.
An ‘off-the-shelf’, cell-free, artificial cardiac patch has been created that is easy to store and improves outcomes in rat and pig models of myocardial infarction.
Apixaban therapy is as effective as low-molecular-weight heparin therapy for the prevention of recurrence of venous thromboembolism in patients with cancer, with no increase in major bleeding events, according to findings from the Caravaggio trial.
Findings from the VOYAGER PAD study show that adding rivaroxaban to standard aspirin therapy can reduce ischaemic risk in patients with peripheral artery disease who have undergone lower-extremity revascularization.
An initial invasive strategy in addition to medical therapy does not reduce the risk of death or nonfatal myocardial infarction or relieve angina symptoms compared with an initial conservative strategy with medical therapy alone in patients with stable coronary artery disease, moderate or severe ischaemia and advanced chronic kidney disease.
Findings from the VICTORIA study show that vericiguat treatment can significantly reduce cardiovascular death or first hospitalization for heart failure in patients with worsening heart failure with reduced ejection fraction.
The addition of an invasive strategy (angiography plus revascularization when feasible) to medical therapy does not reduce the risk of cardiovascular events or death but might reduce symptoms of angina among patients with stable coronary artery disease and moderate or severe ischaemia.
Renal denervation compared with a sham procedure can significantly reduce 24-h and office systolic blood pressure levels in patients with uncontrolled hypertension who are not receiving antihypertensive drugs.
The combination of oral anticoagulation and the antiplatelet drug clopidogrel increases the risk of bleeding after transcatheter aortic valve implantation (TAVI) compared with oral anticoagulation alone, according to the results of the POPular TAVI trial cohort B.
The safety and durability of the LDL-cholesterol-lowering effects of inclisiran, a small interfering RNA that inhibits the synthesis of PCSK9 in the liver, have now been confirmed in three phase III clinical trials published in the New England Journal of Medicine.
A novel metabolite derived from gut microbiota has been shown to promote platelet hyper-responsiveness and modulate platelet function via adrenergic receptors, contributing to increased thrombotic risk.
A surgical mouse model of recurrent myocardial infarction (MI) developed by inducing two sequential MIs in different regions of the same mouse revealed that haematopoietic and innate immune responses are shaped by a preceding MI.
